No Data
No Data
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,235
Here's How Much $100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth Today
What the Options Market Tells Us About Regeneron Pharmaceuticals
Regeneron (REGN) Loses -11.32% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Inquiry Into Regeneron Pharmaceuticals's Competitor Dynamics In Biotechnology Industry
No Data
No Data